Integrated Biopharma Inc (INBP): EBITDA
$2.34M
Year ended 2025-06-30
-$953.0K
Trailing 12 months to 2026-03-31
| Period ended | EBITDA | Change YoY | Source filing |
|---|---|---|---|
| 2025-06-30 | $2.34M | +319.0% | 2025-09-23, From 2024-07-01 |
| 2024-06-30 | $558.0K | n/c | 2025-09-23, From 2023-07-01 |
| 2023-06-30 | $471.0K | -84.7% | 2024-09-20, From 2022-07-01 |
| 2022-06-30 | $3.08M | -49.7% | 2023-09-15, From 2021-07-01 |
| 2021-06-30 | $6.12M | +71.4% | 2022-09-13, From 2020-07-01 |
| 2020-06-30 | $3.57M | +18.0% | 2021-09-02, From 2019-07-01 |
| 2019-06-30 | $3.02M | +48.1% | 2020-09-23, From 2018-07-01 |
| 2018-06-30 | $2.04M | -43.0% | 2019-08-29, From 2017-07-01 |
| 2017-06-30 | $3.58M | +45.2% | 2018-09-12, From 2016-07-01 |
| 2016-06-30 | $2.46M | +84.2% | 2017-09-01, From 2015-07-01 |
| 2015-06-30 | $1.34M | n/a | 2016-09-02, From 2014-07-01 |
| No annual figure between 2013-06-30 and 2015-06-30. | |||
| 2013-06-30 | $1.41M | n/m | 2014-09-08, From 2012-07-01 |
| 2012-06-30 | -$147.0K | n/m | 2013-09-30, From 2011-07-01 |
| 2011-06-30 | -$8.0K | n/a | 2012-10-15, From 2010-07-01 |
EBITDA at similar companies
| Company | Year ended | EBITDA | Change YoY |
|---|---|---|---|
| Integrated Biopharma Inc (INBP) | 2025-06-30 | $2.34M | +319.0% |
| Nektar Therapeutics (NKTR) | 2025-12-31 | -$139.08M | n/m |
| Ocular Therapeutix, Inc (OCUL) | 2025-12-31 | -$265.69M | n/m |
| Aytu Biopharma, Inc (AYTU) | 2026-06-30 | -$4.38M | n/m |
| Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-12-31 | -$48.29M | n/m |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | -$170.70M | n/m |
| Nuvation Bio Inc. (NUVB) | 2025-12-31 | -$211.32M | n/m |
| Protagonist Therapeutics, Inc (PTGX) | 2025-12-31 | -$156.85M | n/m |
| Septerna, Inc. (SEPN) | 2025-12-31 | -$66.70M | n/m |
Compare INBP, NKTR, OCUL, AYTU side by side · Screen every company in Pharmaceutical Preparations ↗